- All sections
- C - Chemistrymetallurgy
- C07F - Acyclic, carbocyclic, or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
- C07F 9/59 - Hydrogenated pyridine rings
Patent holdings for IPC class C07F 9/59
Total number of patents in this class: 139
10-year publication summary
|
13
|
16
|
14
|
20
|
11
|
12
|
10
|
5
|
5
|
0
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4865 |
9 |
| Allergan, Inc. | 2434 |
6 |
| Vertex Pharmaceuticals Incorporated | 1568 |
6 |
| SRX Cardio, LLC | 21 |
5 |
| Glaxosmithkline Intellectual Property (no.2) Limited | 283 |
4 |
| Board of Regents, The University of Texas System | 5627 |
4 |
| Celgene Corporation | 1469 |
4 |
| ChemoCentryx, Inc. | 392 |
4 |
| Novartis AG | 11257 |
3 |
| Northwestern University | 3283 |
3 |
| AM Chemicals LLC | 10 |
3 |
| Amyris, Inc. | 379 |
3 |
| KemPharm, Inc. | 32 |
3 |
| Sarepta Therapeutics, Inc. | 361 |
3 |
| University of Manitoba | 458 |
3 |
| Recurium IP Holdings, LLC | 148 |
3 |
| Zevra Therapeutics, Inc. | 90 |
3 |
| Centre National de La Recherche Scientifique | 10124 |
2 |
| Cardioxyl Pharmaceuticals, Inc. | 49 |
2 |
| Eth Zurich | 1254 |
2 |
| Other owners | 64 |